Four fibroblast groups co-inoculated with cancer cells were compared: no treatment (control), treated with MR16-1 (MR16-1), treated with anti-CD8α antibody (anti-CD8α), and treated with MR16-1 and anti-CD8α (MR16-1 + anti-CD8α). Here, CD8A is linked to cancer.